Page last updated: 2024-12-06
carbobenzoxyvalylphenylalanine aldehyde
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Z-Val-Phe-H : A dipeptide resulting from the formal condensation of the carboxy group of N-benzyloxycarbonyl-L-valine with the amino group of L-phenylalanine aldehyde. It is a potent cell-permeable inhibitor of calpain I and II, and is also a gamma-secretase inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 72430 |
| CHEMBL ID | 286722 |
| CHEBI ID | 82818 |
| SCHEMBL ID | 5133312 |
| MeSH ID | M0162148 |
Synonyms (74)
| Synonym |
|---|
| BRD-K43245338-001-02-4 |
| EU-0100730 |
| lopac-m-6690 |
| NCGC00015696-01 |
| BIO2_000757 |
| BIO2_000277 |
| BSPBIO_001557 |
| IDI1_034027 |
| LOPAC0_000730 |
| MDL 28170 , |
| n-[n-[(phenylmethoxy)carbonyl]-l-valyl]-l-phenylalanine, aldehyde deriv. |
| cbz-val-phe-cho |
| BCBCMAP01_000248 |
| NCGC00094076-03 |
| cbz-val-phe-h |
| cbz-valpheh |
| carbamic acid, (1-(((1-formyl-2-phenylethyl)amino)carbonyl)-2-methylpropyl)-, phenylmethyl ester, (s-(r*,r*))- |
| phenylmethyl ((1s)-1-((((1s)-1-formyl-2-phenylethyl)amino)carbonyl)-2-methylpropyl)carbamate |
| n-cbz-val-phe-al |
| carbobenzoxyvalylphenylalanine aldehyde |
| n-benzyloxycarbonylvalylphenylalaninal |
| n-benzyloxycarbonylvalylphenylalanine aldehyde |
| carbamic acid, ((1s)-1-((((1s)-1-formyl-2-phenylethyl)amino)carbonyl)-2-methylpropyl)-, phenyl ester |
| KBIOSS_000277 |
| KBIO3_000553 |
| KBIO2_005413 |
| KBIO2_002845 |
| KBIOGR_000277 |
| KBIO3_000554 |
| KBIO2_000277 |
| NCGC00094076-01 |
| NCGC00094076-04 |
| NCGC00094076-02 |
| HMS1989N19 |
| M 6690 |
| NCGC00094076-05 |
| CHEMBL286722 , |
| chebi:82818 , |
| benzyl n-[(2s)-3-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]butan-2-yl]carbamate |
| HMS1361N19 |
| HMS1791N19 |
| mdl-2170 |
| benzyl (s)-3-methyl-1-oxo-1-((s)-1-oxo-3-phenylpropan-2-ylamino)butan-2-ylcarbamate |
| [(s)-1-((s)-1-benzyl-2-oxo-ethylcarbamoyl)-2-methyl-propyl]-carbamic acid benzyl ester |
| bdbm50014577 |
| z-val-phe-h |
| HMS3262A22 |
| CCG-204815 |
| unii-wcj9lq197s |
| wcj9lq197s , |
| LP00730 |
| carbamic acid, n-((1s)-1-(((1-formyl-2-phenylethyl)amino)carbonyl)-2-methylpropyl)-, phenylmethyl ester |
| mdl 28,170 |
| z-val-phe-al |
| benzyl [(2s)-3-methyl-1-oxo-1-{[(2s)-1-oxo-3-phenylpropan-2-yl]amino}butan-2-yl]carbamate |
| l-benzyloxycarbonyl-l-valyl-l-phenylalaninal |
| tox21_500730 |
| NCGC00261415-01 |
| SCHEMBL5133312 |
| HMS3402N19 |
| sr-01000076004 |
| SR-01000076004-1 |
| Q27156387 |
| benzyl ((s)-3-methyl-1-oxo-1-(((s)-1-oxo-3-phenylpropan-2-yl)amino)butan-2-yl)carbamate |
| NGBKFLTYGSREKK-PMACEKPBSA-N |
| cbz(l)-val-phe-h |
| 756485-04-8 |
| SDCCGSBI-0050708.P003 |
| NCGC00094076-06 |
| n-benzyloxycarbonyl-l-valyl-l-phenylalaninal |
| gtpl10745 |
| 2-{[(benzyloxy)(hydroxy)methylidene]amino}-3-methyl-n-(1-oxo-3-phenylpropan-2-yl)butanimidic acid |
| DTXSID801007990 |
| mdl-28170; z-val-phe-cho |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (5)
| Role | Description |
|---|---|
| EC 3.4.22.53 (calpain-2) inhibitor | A calpain inhibitor that interferes with the action of calpain-2 (EC 3.4.22.53). |
| EC 3.4.22.52 (calpain-1) inhibitor | A calpain inhibitor that interferes with the action of calpain-1 (EC 3.4.22.52). |
| EC 3.4.23.46 (memapsin 2) inhibitor | An EC 3.4.23.* (aspartic endopeptidase) inhibitor that interferes with the activity of memapsin 2 (EC 3.4.23.46). |
| antileishmanial agent | An antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania. |
| apoptosis inhibitor | Any substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (3)
| Class | Description |
|---|---|
| aldehyde | A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group. |
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| carbamate ester | Any ester of carbamic acid or its N-substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (44)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 0.0316 | 0.0020 | 14.6779 | 39.8107 | AID1476; AID1478 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 0.5012 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 1.7783 | 0.0282 | 7.0559 | 15.8489 | AID895; AID928 |
| TDP1 protein | Homo sapiens (human) | Potency | 34.3043 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 22.3872 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 15.5686 | 0.0015 | 30.6073 | 15,848.9004 | AID1224819; AID1224820; AID1224821 |
| arylsulfatase A | Homo sapiens (human) | Potency | 2.3934 | 1.0691 | 13.9551 | 37.9330 | AID720538 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 41.4568 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 0.0004 | 0.5406 | 17.6392 | 96.1227 | AID2364; AID2528 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 10.6910 | 23.9341 | 23.9341 | 23.9341 | AID1967 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 39.8107 | 0.0063 | 6.9043 | 39.8107 | AID883 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 2.0595 | 0.0224 | 5.9449 | 22.3872 | AID488982 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 70.7946 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 1.5849 | 0.0100 | 39.5371 | 1,122.0200 | AID1479 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 0.2818 | 0.1000 | 28.9256 | 213.3130 | AID588591 |
| geminin | Homo sapiens (human) | Potency | 14.1254 | 0.0046 | 11.3741 | 33.4983 | AID463097 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 6.3096 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 56.2341 | 0.1778 | 24.7352 | 79.4328 | AID488949 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.2512 | 15.8432 | 39.8107 | AID504327 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 0.0141 | 0.0010 | 6.0009 | 35.4813 | AID944 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 18.8541 | 0.8913 | 12.0676 | 28.1838 | AID1459; AID1487 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 39.8107 | 0.0063 | 8.2350 | 39.8107 | AID883 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chymotrypsinogen A | Bos taurus (cattle) | Ki | 54.0000 | 0.9000 | 4.0000 | 8.7000 | AID219281 |
| Calpain-1 catalytic subunit | Homo sapiens (human) | IC50 (µMol) | 0.3000 | 0.0002 | 1.0592 | 10.0000 | AID46723 |
| Calpain-1 catalytic subunit | Homo sapiens (human) | Ki | 0.0080 | 0.0070 | 0.0181 | 0.0560 | AID46727 |
| Cathepsin B | Homo sapiens (human) | Ki | 0.0240 | 0.0000 | 1.2180 | 8.6000 | AID50287 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 20.0000 | 0.0002 | 2.4585 | 9.9600 | AID1845236 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.3000 | 0.0005 | 1.4835 | 7.8000 | AID46723 |
| Calpain-1 catalytic subunit | Sus scrofa (pig) | Ki | 0.0100 | 0.0100 | 0.8640 | 3.9600 | AID1662230 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (17)
Molecular Functions (18)
Ceullar Components (22)
Bioassays (40)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347410 | qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library | 2019 | Cellular signalling, 08, Volume: 60 | A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening. |
| AID504836 | Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation | 2002 | The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16 | Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. |
| AID588378 | qHTS for Inhibitors of ATXN expression: Validation | |||
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347045 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1347059 | CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347057 | CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347049 | Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1347058 | CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation | 2019 | PloS one, , Volume: 14, Issue:7 | Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. |
| AID1347050 | Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay | 2019 | Science translational medicine, 07-10, Volume: 11, Issue:500 | Inhibition of natriuretic peptide receptor 1 reduces itch in mice. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID588349 | qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay | |||
| AID1347405 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347151 | Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID46729 | Inhibitory activity against Calpain-II receptor in porcine kidney; Not determined | 1998 | Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15 | D-amino acid containing, high-affinity inhibitors of recombinant human calpain I. |
| AID1916513 | Antileishmanial activity against Leishmania amazonensis promastigotes assessed as reduction in parasite survival measured after 48 hrs by Neubauer counting chamber based analysis | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | Cysteine proteases as potential targets for anti-trypanosomatid drug discovery. |
| AID46333 | Inhibition of Calpain | 1990 | Journal of medicinal chemistry, Jan, Volume: 33, Issue:1 | Alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. |
| AID219281 | Inhibition of alpha-chymotrypsin | 1990 | Journal of medicinal chemistry, Jan, Volume: 33, Issue:1 | Alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. |
| AID36978 | Inhibitory activity against Bovine pancreas alpha-chymotrypsin at 10 uM; Not determined | 1998 | Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15 | D-amino acid containing, high-affinity inhibitors of recombinant human calpain I. |
| AID1916516 | Antitrypanosomal activity against bloodstream Trypanosoma cruzi Y strain trypomastigote assessed as reduction in parasite viability incubated for 24 hrs by Neubauer chamber based analysis | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | Cysteine proteases as potential targets for anti-trypanosomatid drug discovery. |
| AID1662229 | Antiproliferative activity against human A375 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay | 2020 | Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9 | Synthesis and antiproliferative activity of sulfonamide-based peptidomimetic calpain inhibitors. |
| AID210832 | Inhibitory activity against human plasma thrombin at 10 uM; Not determined | 1998 | Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15 | D-amino acid containing, high-affinity inhibitors of recombinant human calpain I. |
| AID1662227 | Antiproliferative activity against human PC3 cells assessed as inhibition of cell growth after 72 hrs by MTT assay | 2020 | Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9 | Synthesis and antiproliferative activity of sulfonamide-based peptidomimetic calpain inhibitors. |
| AID1845236 | Inhibition of SARS-CoV-2 MPro | 2021 | Bioorganic & medicinal chemistry, 01-01, Volume: 29 | Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. |
| AID1916515 | Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes assessed as reduction in parasite viability incubated for 48 hrs by trypan blue staining based Neubauer counting chamber analysis | 2021 | Bioorganic & medicinal chemistry, 09-15, Volume: 46 | Cysteine proteases as potential targets for anti-trypanosomatid drug discovery. |
| AID46727 | Inhibitory activity against recombinant human Calpain-I receptor | 1998 | Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15 | D-amino acid containing, high-affinity inhibitors of recombinant human calpain I. |
| AID46723 | Inhibition of intracellular Calpain-I receptor using intact cell assay system | 1998 | Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15 | D-amino acid containing, high-affinity inhibitors of recombinant human calpain I. |
| AID50287 | Inhibitory activity against cathepsin B receptor in human liver | 1998 | Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15 | D-amino acid containing, high-affinity inhibitors of recombinant human calpain I. |
| AID1662230 | Inhibition of mu-calpain in porcine erythrocyte using Suc-Leu-Tyr-AMC as substrate by microtiter plate assay based Dixon plot analysis | 2020 | Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9 | Synthesis and antiproliferative activity of sulfonamide-based peptidomimetic calpain inhibitors. |
| AID1662228 | Antiproliferative activity against mouse B16-F1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B colorimetric assay | 2020 | Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9 | Synthesis and antiproliferative activity of sulfonamide-based peptidomimetic calpain inhibitors. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (20)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 8 (40.00) | 24.3611 |
| 2020's | 9 (45.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.04
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.04) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||